patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_577592 | REC_0008101 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 12.3 | 63 | male | 1 | 6 | 6.9 | 4 | alectinib 600 mg BID | 15.8 | true | MSI-H | 2026-03-15T05:35:58.842971+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_552921 | REC_0008102 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 13.5 | 59 | female | 0 | 9 | 6 | 6 | sotorasib 960 mg daily | 9.5 | false | MSS | 2026-03-15T05:35:58.843208+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_153855 | REC_0008103 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 17 | 9.9 | 70 | female | 0 | 17 | 5.2 | 5 | alectinib 600 mg BID | 11.9 | true | MSS | 2026-03-15T05:35:58.843440+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_452966 | REC_0008104 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 21 | 7.2 | 54 | female | 0 | 46 | 5.9 | 1 | carboplatin + paclitaxel + pembrolizumab | 24.4 | false | MSS | 2026-03-15T05:35:58.843672+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_414002 | REC_0008105 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 34 | 14.4 | 68 | female | 0 | 17 | 4.5 | 4 | osimertinib 80 mg daily | 20.1 | false | MSI-H | 2026-03-15T05:35:58.843909+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_760809 | REC_0008106 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 27 | 11.3 | 63 | male | 0 | 17 | 6.8 | 4 | osimertinib 80 mg daily | 10.3 | true | MSI-H | 2026-03-15T05:35:58.844190+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_312856 | REC_0008107 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 18.8 | 69 | male | 1 | 21 | 3.9 | 7 | osimertinib 80 mg daily | 7.2 | false | MSS | 2026-03-15T05:35:58.844435+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_732436 | REC_0008108 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 15 | 13.9 | 72 | female | 1 | 11 | 6.6 | 5 | osimertinib 80 mg daily | 8.5 | true | MSI-H | 2026-03-15T05:35:58.844678+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_906410 | REC_0008109 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 13.9 | 66 | female | 0 | 15 | 6 | 8 | alectinib 600 mg BID | 10 | true | MSS | 2026-03-15T05:35:58.844915+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_505903 | REC_0008110 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 29 | 12.8 | 76 | female | 2 | 17 | 5.8 | 6 | alectinib 600 mg BID | 10.2 | true | MSI-H | 2026-03-15T05:35:58.845145+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_719980 | REC_0008111 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 25 | 12.5 | 62 | female | 1 | 10 | 4.1 | 2 | alectinib 600 mg BID | 29 | false | MSS | 2026-03-15T05:35:58.845382+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_120511 | REC_0008112 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 29 | 16.8 | 72 | male | 2 | 20 | 4.3 | 1 | osimertinib 80 mg daily | 25.5 | true | MSI-H | 2026-03-15T05:35:58.845617+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_433670 | REC_0008113 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 34 | 5.5 | 69 | female | 0 | 14 | 6.6 | 0 | pembrolizumab 200 mg q3w | 12 | false | MSS | 2026-03-15T05:35:58.845894+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_962072 | REC_0008114 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 14 | 78 | male | 2 | 13 | 4.3 | 4 | alectinib 600 mg BID | 11.6 | true | MSS | 2026-03-15T05:35:58.846134+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_205333 | REC_0008115 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 21 | 9.1 | 73 | female | 2 | 12 | 5.6 | 1 | alectinib 600 mg BID | 14 | true | MSS | 2026-03-15T05:35:58.846369+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_841558 | REC_0008116 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 22 | 7 | 61 | female | 0 | 21 | 4.3 | 5 | pembrolizumab 200 mg q3w | 18.5 | true | MSS | 2026-03-15T05:35:58.846612+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_752374 | REC_0008117 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 23 | 7.6 | 52 | male | 0 | 20 | 5.3 | 1 | osimertinib 80 mg daily | 4 | false | MSS | 2026-03-15T05:35:58.846858+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_989182 | REC_0008118 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 16.9 | 64 | male | 1 | 18 | 5.1 | 6 | entrectinib 600 mg daily | 5.9 | true | MSI-H | 2026-03-15T05:35:58.847098+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_873188 | REC_0008119 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 24 | 12.5 | 53 | female | 0 | 7 | 6.7 | 1 | osimertinib 80 mg daily | 22.9 | false | MSS | 2026-03-15T05:35:58.847337+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_744390 | REC_0008120 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 27 | 11.6 | 65 | female | 1 | 6 | 6.4 | 5 | sotorasib 960 mg daily | 18.4 | true | MSS | 2026-03-15T05:35:58.847575+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_225809 | REC_0008121 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 6.4 | 58 | male | 0 | 39 | 6.8 | 5 | carboplatin + paclitaxel + pembrolizumab | 18.1 | true | MSS | 2026-03-15T05:35:58.847808+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_787677 | REC_0008122 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 28 | 12.5 | 55 | female | 1 | 13 | 5.4 | 5 | osimertinib 80 mg daily | 8.5 | false | MSS | 2026-03-15T05:35:58.848043+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_979190 | REC_0008123 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 19 | 15.2 | 67 | female | 0 | 11 | 5.8 | 1 | alectinib 600 mg BID | 27.9 | false | MSI-H | 2026-03-15T05:35:58.848319+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_365456 | REC_0008124 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 20.1 | 63 | female | 0 | 21 | 6.5 | 5 | sotorasib 960 mg daily | 16.2 | false | MSI-H | 2026-03-15T05:35:58.848561+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_792768 | REC_0008125 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 22 | 11.4 | 64 | male | 1 | 11 | 4.2 | 2 | sotorasib 960 mg daily | 15.7 | true | MSI-H | 2026-03-15T05:35:58.848886+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_519266 | REC_0008126 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 22 | 4.4 | 76 | female | 1 | 34 | 7.4 | 5 | carboplatin + paclitaxel + pembrolizumab | 10.5 | false | MSS | 2026-03-15T05:35:58.849244+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_290037 | REC_0008127 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 34 | 6.8 | 55 | male | 1 | 34 | 6.6 | 5 | carboplatin + paclitaxel + pembrolizumab | 8.4 | false | MSS | 2026-03-15T05:35:58.849502+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_622885 | REC_0008128 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 25 | 14.2 | 61 | female | 0 | 19 | 3.1 | 1 | alectinib 600 mg BID | 18.4 | false | MSI-H | 2026-03-15T05:35:58.849742+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_190107 | REC_0008129 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 31 | 16.8 | 56 | female | 1 | 15 | 3.5 | 7 | pembrolizumab 200 mg q3w | 10.2 | true | MSI-H | 2026-03-15T05:35:58.849985+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_349594 | REC_0008130 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 8.2 | 68 | male | 0 | 61 | 5.7 | 5 | carboplatin + paclitaxel + pembrolizumab | 17.9 | true | MSS | 2026-03-15T05:35:58.850221+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_570437 | REC_0008131 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 26 | 14.8 | 58 | female | 0 | 23 | 4.1 | 1 | sotorasib 960 mg daily | 11.8 | false | MSS | 2026-03-15T05:35:58.850457+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_255770 | REC_0008132 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 25 | 13.3 | 81 | female | 2 | 24 | 5.4 | 9 | pembrolizumab 200 mg q3w | 6.5 | true | MSS | 2026-03-15T05:35:58.850734+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_471145 | REC_0008133 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 29 | 4.8 | 66 | male | 1 | 23 | 3.7 | 5 | osimertinib 80 mg daily | 17.7 | true | MSS | 2026-03-15T05:35:58.851017+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_957765 | REC_0008134 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 32 | 14 | 56 | female | 0 | 13 | 5.8 | 6 | sotorasib 960 mg daily | 9.8 | false | MSS | 2026-03-15T05:35:58.851266+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_306968 | REC_0008135 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 18 | 7.8 | 77 | male | 2 | 16 | 6.3 | 7 | sotorasib 960 mg daily | 16.3 | true | MSS | 2026-03-15T05:35:58.851516+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_404506 | REC_0008136 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 20 | 15 | 73 | female | 0 | 14 | 6.8 | 5 | osimertinib 80 mg daily | 15.3 | false | MSI-H | 2026-03-15T05:35:58.851752+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_716487 | REC_0008137 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 26 | 14.7 | 71 | female | 2 | 15 | 4 | 3 | entrectinib 600 mg daily | 17.4 | true | MSI-H | 2026-03-15T05:35:58.851984+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_508051 | REC_0008138 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 21 | 7.7 | 58 | male | 0 | 12 | 4.1 | 5 | alectinib 600 mg BID | 7.7 | false | MSS | 2026-03-15T05:35:58.852291+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_580713 | REC_0008139 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 28 | 8.5 | 52 | female | 0 | 8 | 6 | 1 | pembrolizumab 200 mg q3w | 16.3 | false | MSS | 2026-03-15T05:35:58.852618+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_364559 | REC_0008140 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 13.1 | 68 | female | 1 | 16 | 7.6 | 6 | entrectinib 600 mg daily | 9.3 | false | MSS | 2026-03-15T05:35:58.852860+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_658611 | REC_0008141 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 28 | 8.8 | 76 | female | 2 | 10 | 5.1 | 2 | osimertinib 80 mg daily | 13.5 | false | MSS | 2026-03-15T05:35:58.853091+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_520305 | REC_0008142 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 25 | 10.1 | 66 | female | 1 | 12 | 6.4 | 1 | osimertinib 80 mg daily | 35.7 | false | MSS | 2026-03-15T05:35:58.853324+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_260485 | REC_0008143 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 26 | 11.1 | 66 | female | 1 | 10 | 3.6 | 1 | osimertinib 80 mg daily | 25.6 | true | MSS | 2026-03-15T05:35:58.853563+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_684012 | REC_0008144 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 23 | 19.1 | 78 | female | 2 | 9 | 4 | 1 | osimertinib 80 mg daily | 14.6 | true | MSI-H | 2026-03-15T05:35:58.853800+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_450186 | REC_0008145 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 19 | 13.5 | 72 | female | 1 | 14 | 5.4 | 2 | sotorasib 960 mg daily | 10.5 | false | MSI-H | 2026-03-15T05:35:58.854033+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_838594 | REC_0008146 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 24 | 9.5 | 66 | female | 1 | 22 | 7 | 1 | osimertinib 80 mg daily | 11.6 | false | MSS | 2026-03-15T05:35:58.854265+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_705304 | REC_0008147 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 8.5 | 66 | female | 0 | 10 | 4.9 | 6 | osimertinib 80 mg daily | 9 | true | MSS | 2026-03-15T05:35:58.854497+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_200609 | REC_0008148 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 19.9 | 75 | male | 0 | 0 | 7.1 | 6 | osimertinib 80 mg daily | 16.2 | true | MSI-H | 2026-03-15T05:35:58.854730+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_635574 | REC_0008149 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 4.2 | 76 | male | 1 | 37 | 7.4 | 6 | carboplatin + paclitaxel + pembrolizumab | 16.7 | false | MSS | 2026-03-15T05:35:58.854962+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_852034 | REC_0008150 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 27 | 13.6 | 58 | male | 1 | 16 | 6.4 | 0 | sotorasib 960 mg daily | 47.1 | true | MSI-H | 2026-03-15T05:35:58.855198+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_726339 | REC_0008151 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 24 | 6 | 85 | female | 0 | 18 | 2 | 6 | pembrolizumab 200 mg q3w | 20.9 | true | MSS | 2026-03-15T05:35:58.855428+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_370340 | REC_0008152 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 12 | 78 | female | 2 | 15 | 6.7 | 3 | osimertinib 80 mg daily | 10.1 | true | MSS | 2026-03-15T05:35:58.855711+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_788933 | REC_0008153 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 25 | 2.4 | 66 | female | 1 | 16 | 3.1 | 6 | pembrolizumab 200 mg q3w | 5.1 | false | MSS | 2026-03-15T05:35:58.855981+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_503551 | REC_0008154 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 21 | 9.7 | 65 | female | 1 | 39 | 8.4 | 5 | pembrolizumab 200 mg q3w | 12.8 | true | MSS | 2026-03-15T05:35:58.856359+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_456123 | REC_0008155 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 12.3 | 70 | male | 3 | 21 | 4.4 | 7 | osimertinib 80 mg daily | 12.1 | true | MSI-H | 2026-03-15T05:35:58.856625+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_811317 | REC_0008156 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 19 | 12 | 62 | female | 1 | 22 | 5.8 | 2 | osimertinib 80 mg daily | 9.6 | true | MSI-H | 2026-03-15T05:35:58.856882+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_584437 | REC_0008157 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 29 | 15.7 | 84 | female | 1 | 19 | 7.5 | 4 | sotorasib 960 mg daily | 10.1 | true | MSI-H | 2026-03-15T05:35:58.857192+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_773770 | REC_0008158 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 24 | 10.4 | 57 | male | 1 | 14 | 6.1 | 2 | alectinib 600 mg BID | 10.2 | false | MSI-H | 2026-03-15T05:35:58.857443+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_149202 | REC_0008159 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 29 | 14 | 73 | male | 1 | 7 | 6.1 | 4 | osimertinib 80 mg daily | 10.4 | false | MSS | 2026-03-15T05:35:58.857734+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_418605 | REC_0008160 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 23 | 8.3 | 59 | female | 0 | 15 | 5.2 | 5 | entrectinib 600 mg daily | 10.9 | true | MSS | 2026-03-15T05:35:58.858017+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_781224 | REC_0008161 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 19 | 9.3 | 77 | female | 1 | 19 | 7.5 | 1 | pembrolizumab 200 mg q3w | 23.4 | false | MSS | 2026-03-15T05:35:58.858300+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_209506 | REC_0008162 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 9.3 | 72 | female | 2 | 17 | 3.8 | 4 | alectinib 600 mg BID | 15.6 | true | MSS | 2026-03-15T05:35:58.858580+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_248860 | REC_0008163 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 28 | 11.8 | 78 | female | 2 | 19 | 5.1 | 8 | alectinib 600 mg BID | 14.8 | false | MSI-H | 2026-03-15T05:35:58.858938+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_901274 | REC_0008164 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 27 | 14.2 | 68 | female | 0 | 6 | 6.5 | 2 | sotorasib 960 mg daily | 13.2 | false | MSI-H | 2026-03-15T05:35:58.859302+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_306082 | REC_0008165 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 28 | 10.6 | 76 | female | 3 | 10 | 7.9 | 5 | sotorasib 960 mg daily | 6.2 | true | MSI-H | 2026-03-15T05:35:58.859796+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_455329 | REC_0008166 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 12.8 | 84 | female | 1 | 0 | 6.4 | 4 | alectinib 600 mg BID | 4.4 | true | MSS | 2026-03-15T05:35:58.860245+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_577492 | REC_0008167 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 19 | 15.4 | 67 | female | 1 | 0 | 7.3 | 5 | osimertinib 80 mg daily | 13.4 | false | MSS | 2026-03-15T05:35:58.860521+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_274983 | REC_0008168 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 20 | 11.9 | 57 | male | 1 | 7 | 4.3 | 5 | osimertinib 80 mg daily | 10.6 | true | MSI-H | 2026-03-15T05:35:58.860791+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_600224 | REC_0008169 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 25 | 20.9 | 75 | female | 3 | 23 | 6.1 | 1 | sotorasib 960 mg daily | 24.5 | false | MSS | 2026-03-15T05:35:58.861156+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_719472 | REC_0008170 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 21 | 9.3 | 63 | female | 1 | 20 | 5 | 3 | entrectinib 600 mg daily | 10.3 | true | MSS | 2026-03-15T05:35:58.861407+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_107376 | REC_0008171 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 22 | 17.6 | 62 | female | 1 | 20 | 5 | 5 | entrectinib 600 mg daily | 10.3 | false | MSI-H | 2026-03-15T05:35:58.861665+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_438139 | REC_0008172 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 25 | 8.9 | 75 | female | 1 | 19 | 5.4 | 2 | alectinib 600 mg BID | 18.3 | true | MSS | 2026-03-15T05:35:58.861907+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_810441 | REC_0008173 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 28 | 8.7 | 53 | female | 0 | 20 | 4.2 | 8 | osimertinib 80 mg daily | 10 | true | MSS | 2026-03-15T05:35:58.862159+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_116431 | REC_0008174 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 12.7 | 67 | male | 1 | 15 | 5.4 | 6 | osimertinib 80 mg daily | 7.3 | false | MSI-H | 2026-03-15T05:35:58.862425+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_143638 | REC_0008175 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 17 | 10.5 | 60 | female | 1 | 13 | 5.5 | 3 | osimertinib 80 mg daily | 19.6 | true | MSI-H | 2026-03-15T05:35:58.862677+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_775003 | REC_0008176 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 18 | 12.2 | 57 | female | 1 | 13 | 4.8 | 1 | entrectinib 600 mg daily | 17.3 | true | MSS | 2026-03-15T05:35:58.862933+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_965837 | REC_0008177 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 28 | 15.3 | 53 | male | 0 | 19 | 8.4 | 5 | osimertinib 80 mg daily | 10.2 | false | MSS | 2026-03-15T05:35:58.863192+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_988841 | REC_0008178 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 15.4 | 54 | male | 0 | 19 | 5 | 4 | osimertinib 80 mg daily | 15.9 | true | MSS | 2026-03-15T05:35:58.863566+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_622614 | REC_0008179 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 24 | 6.9 | 83 | female | 2 | 33 | 4 | 5 | pembrolizumab 200 mg q3w | 7.4 | true | MSS | 2026-03-15T05:35:58.864217+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_598980 | REC_0008180 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 26 | 12.2 | 65 | female | 0 | 11 | 4.7 | 6 | osimertinib 80 mg daily | 4.2 | false | MSI-H | 2026-03-15T05:35:58.864484+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_863321 | REC_0008181 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 29 | 8 | 72 | female | 2 | 20 | 4.8 | 6 | entrectinib 600 mg daily | 19 | true | MSS | 2026-03-15T05:35:58.864920+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_157747 | REC_0008182 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 19 | 14.1 | 57 | male | 1 | 7 | 5.2 | 2 | pembrolizumab 200 mg q3w | 18.5 | false | MSS | 2026-03-15T05:35:58.865210+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_767455 | REC_0008183 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 23 | 14.3 | 87 | female | 2 | 5 | 6.3 | 2 | entrectinib 600 mg daily | 18.6 | true | MSS | 2026-03-15T05:35:58.865512+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_532230 | REC_0008184 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 22 | 9.8 | 68 | female | 0 | 19 | 5 | 5 | entrectinib 600 mg daily | 10.3 | true | MSS | 2026-03-15T05:35:58.865823+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_926572 | REC_0008185 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 21 | 17.6 | 63 | female | 0 | 12 | 5.4 | 1 | pembrolizumab 200 mg q3w | 22.9 | false | MSI-H | 2026-03-15T05:35:58.866075+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_159645 | REC_0008186 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 29 | 13.2 | 69 | female | 1 | 16 | 5.2 | 5 | alectinib 600 mg BID | 17.3 | false | MSI-H | 2026-03-15T05:35:58.866422+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_179951 | REC_0008187 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 24 | 6.7 | 70 | female | 1 | 14 | 5.3 | 2 | osimertinib 80 mg daily | 27.1 | true | MSS | 2026-03-15T05:35:58.866667+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_438186 | REC_0008188 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 33 | 15.6 | 67 | female | 1 | 20 | 4.2 | 5 | entrectinib 600 mg daily | 13.1 | true | MSS | 2026-03-15T05:35:58.867168+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_178780 | REC_0008189 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 21 | 6.5 | 64 | male | 1 | 11 | 4.9 | 2 | pembrolizumab 200 mg q3w | 12 | true | MSS | 2026-03-15T05:35:58.867789+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_137205 | REC_0008190 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 15 | 10.7 | 78 | male | 0 | 13 | 3.9 | 8 | sotorasib 960 mg daily | 15.6 | true | MSS | 2026-03-15T05:35:58.868039+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_894063 | REC_0008191 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 13.7 | 73 | female | 2 | 22 | 3.5 | 6 | sotorasib 960 mg daily | 7.8 | true | MSI-H | 2026-03-15T05:35:58.868513+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_276900 | REC_0008192 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 4.8 | 65 | male | 1 | 40 | 5.7 | 5 | carboplatin + paclitaxel + pembrolizumab | 4.5 | false | MSS | 2026-03-15T05:35:58.868799+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_771733 | REC_0008193 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 24 | 14 | 69 | male | 0 | 8 | 6.9 | 1 | osimertinib 80 mg daily | 23.3 | true | MSS | 2026-03-15T05:35:58.869062+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_488952 | REC_0008194 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 27 | 4.4 | 70 | female | 1 | 27 | 5.9 | 5 | pembrolizumab 200 mg q3w | 13.7 | false | MSS | 2026-03-15T05:35:58.869325+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_956810 | REC_0008195 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 22 | 8.4 | 65 | male | 1 | 47 | 4.8 | 0 | carboplatin + paclitaxel + pembrolizumab | 25.2 | false | MSS | 2026-03-15T05:35:58.869582+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_208378 | REC_0008196 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 30 | 9.3 | 63 | male | 0 | 12 | 6.6 | 3 | osimertinib 80 mg daily | 12.8 | false | MSS | 2026-03-15T05:35:58.869835+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_355813 | REC_0008197 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 10.6 | 69 | female | 1 | 17 | 6 | 3 | alectinib 600 mg BID | 16.8 | true | MSI-H | 2026-03-15T05:35:58.870088+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_839655 | REC_0008198 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 20 | 5.9 | 83 | male | 3 | 48 | 7.4 | 2 | carboplatin + paclitaxel + pembrolizumab | 20.8 | false | MSS | 2026-03-15T05:35:58.870337+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_407823 | REC_0008199 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 15 | 13.5 | 69 | female | 1 | 11 | 8.1 | 1 | osimertinib 80 mg daily | 19.7 | false | MSS | 2026-03-15T05:35:58.870608+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_877409 | REC_0008200 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 19 | 3.7 | 77 | female | 2 | 30 | 5.2 | 2 | carboplatin + paclitaxel + pembrolizumab | 11.1 | false | MSS | 2026-03-15T05:35:58.870864+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.